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Background: Little is known about whether or how supplemental oxygen affects patients with pulmonary fibrosis.
Methods/Design: A mixed-methods study is described. Patients with pulmonary fibrosis, informal caregivers of
pulmonary fibrosis patients and practitioners who prescribe supplemental oxygen will be interviewed to gather data
on perceptions of how supplemental oxygen impacts patients. In addition, three hundred pulmonary fibrosis
patients who do not use daytime supplemental oxygen will be recruited to participate in a longitudinal, pre-/post- study
in which patient-reported outcome (PRO) and activity data will be collected at baseline, immediately before daytime
supplemental oxygen is initiated, and then once and again 9–12 months later. Activity data will be collected using
accelerometers and portable GPS data recorders. The primary outcome is change in dyspnea from before to one month
after supplemental oxygen is initiated. Secondary outcomes include scores from PROs to assess cough, fatigue and
quality of life as well as the activity data. In exploratory analyses, we will use longitudinal data analytic techniques to
assess the trajectories of outcomes over time while controlling for potentially influential variables.
Discussion: Throughout the study and at its completion, results will be posted on the website for our research
program (the Participation Program for Pulmonary Fibrosis or P3F) at www.pulmonaryfibrosisresearch.org.Background
Pulmonary fibrosis (PF) is a chronic lung disease in which
the normally thin, delicate alveolar walls are infiltrated by
extracellular matrix and mature, inelastic collagen, leaving
them irreversibly thickened and dysfunctional [1]. The stiff
lungs of patients with PF hold less air than normal and do
not allow transfer of oxygen from airspace to bloodstream.
Clinically, this leads to low blood oxygen levels and short-
ness of breath.
PF can be caused by a number of entities, including
connective tissue diseases (e.g., rheumatoid arthritis),
but most commonly, it exists as an idiopathic condition,
in which case, despite extensive investigation, its cause
remains unknown. Whether of known-cause or idio-
pathic, PF is a challenging disease for patients to live* Correspondence: swigrisj@njc.org
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unless otherwise stated.with: it typically progresses and shortens survival; its
symptoms—shortness of breath, nagging cough and fa-
tigue—limit physical and social activities and impair pa-
tients’ quality of life (QOL) [2,3]; and there is no cure.
At some point in their illness, many PF patients will
develop low blood oxygen levels when sleeping, exerting
and/or at rest [4,5]. Such patients may be prescribed
supplemental oxygen (O2) to maintain normal blood
oxygen levels. Current research suggests PF patients and
their informal caregivers (spouse/partner/loved one) typ-
ically view O2 with extreme resignation: it is a visible re-
minder of disease progression; the equipment can be
heavy and cumbersome to lug around; and having to
deal with O2 forces patients to strategize before leaving
home for the day (extended travel creates even greater
logistical issues). In short, O2 is viewed by many PF pa-
tients as an unwanted but necessary burden [6,7].
Studies have shown that, in certain patients with
chronic obstructive pulmonary disease (COPD), O2 can
prolong survival, improve physical functioning and im-
prove QOL [8,9]. But even the data for O2 in COPD—td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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world—are surprisingly scant. And despite the nearly
universal need for O2 among PF patients, even less is
known about whether or how O2 affects their physical
functioning, symptoms and QOL [10,11]. Currently, be-
cause of the paucity of data to inform them, PF patients
and prescribers lack sound, quantifiable evidence needed
to answer patients when they ask critical questions, such
as, why is supplemental oxygen important? And what
can I expect to gain by using oxygen?
The members of our team—called the Participation
Program for Pulmonary Fibrosis (P3F)—which includes
professionals as well as people living with PF, have de-
signed a rigorous mixed-methods study in an attempt to
systematically answer these and other questions about
O2 in PF (see Table 1). Subjects recruited from across
the nation will have qualitative, quantitative or both
types of data collected either once or up to four times,
depending on whether they use O2 during the day at en-
rollment. In the qualitative piece, we are collecting percep-
tions of O2 from PF patients, informal caregivers (ICs) of
PF patients and from prescribers of O2 to PF patients. In
the quantitative piece, we are using a pre-/post- study
design to measure the effect of O2 on a wide range of
patient-centered outcomes, including dyspnea, QOL,
fatigue, cough, day-to-day functioning and activity space (a
medical geography term referring to the extent of the en-
vironment used by an individual) in patients with PF.
We will test the working hypothesis that compared
with just prior to starting O2, after one month of use,
outcomes will be better (primary outcome is shortness
of breath with secondary outcomes being QOL, fatigue,
cough, functioning and activity space). A secondary hy-
pothesis we will test is compared with just prior to
starting O2, these outcomes will remain improved after
9–12 months. In this manuscript, we detail the study
design.Table 1 Mixed-methodology study design
Category
1. PF patients who have used O2 for at least eight months
2. ICs of PF patients who have used O2 for at least eight months
3. Practitioners who have prescribed O2 for at least one patient with PF
4. PF patients not on daily-use O2 at enrollment
QUAL = qualitative data collection; QUANT = quantitative data collection; PRO = patiMethods
Enrollment
Study participants will be recruited through an assortment
of efforts. Our main method of advertising is through the
P3F website (www.pulmonaryfibrosisresearch.org) where
people can find information about the study and contact
P3F coordinators, or they have the option to sign up for
our Contact Registry which gives P3F coordinators permis-
sion to contact patients directly. We have also enlisted the
help of patients and professionals from all over the US—
physicians, nurses, research coordinators, support group
leaders—to spread the word about our program and study.
We have also utilized other internet-based outlets such as
online support groups and social media (Facebook and
Twitter) to increase the reach of our program and study.
We will enroll subjects into one of four categories: 1)
PF patients who use daytime O2; 2) ICs of PF patients
who use daytime O2; 3) physicians who prescribe day-
time O2 to PF patients; and 4) PF patients who do not
use daytime O2 (they will participate in the pre-/post-
O2 longitudinal study). The consent process will be con-
ducted via mail, e-mail or fax for all patient-participants
and over the phone for ICs and physicians.
Inclusion criteria
All persons enrolled in the study must be able to speak
and read English and be at least 18 years of age. Patients
will be eligible to participate if they have a diagnosis of
PF and, at time of enrollment, have either been using
daytime oxygen for at least eight months or are not
using daytime O2 at all. ICs must self-report their status
as caregiver to someone with PF who has used daytime
O2 for at least eight months. Physicians must have pre-
scribed O2 to at least one PF patient.
PF patients in category 4 (no daytime O2 at enroll-
ment) must obtain permission from their physicians to
wait seven-ten days before starting daytime O2. ThisN Study design Method Data collection
20 X-sectional QUAL Interview
QUANT PRO Questionnaires
20 X-sectional QUAL Interview
20 X-sectional QUAL Interview




260 Longitudinal QUANT PRO Questionnaires
GPS
Accelerometer
ent-reported outcome measure; GPS = global positioning system.
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starting O2. When these category 4 patients enroll, we
will send them a Patient-Doctor Visit Study Packet
which includes a letter to both parties reminding them
of the terms of the study. The doctor of the patient-
participant will sign and fax to the P3F team a memoran-
dum agreeing to the terms of the study, including having
the participant wait to start daily-use O2 for seven-ten
days after it is prescribed.
Study overview
Quantitative data will be collected through question-
naires and GPS and accelerometer devices (see section
titled “Quantitative data collection” for more details on
these modes of data collection). Quantitative data will be
captured once for patients in category 1 and at four time
points for patients in category 4 (the longitudinal study):
1) at enrollment; 2) just prior to daily-use O2 initiation;
3) one month after starting daytime O2; and 4) 9–12
months after starting daytime O2.
For patients in the longitudinal arm, beginning at en-
rollment, we will also collect monthly response data for
the University of California San Diego Shortness of
Breath Questionnaire (or UCSD). Doing so gives us the
opportunity to plot rich trajectories for dyspnea and to
detect subtleties that might be missed with a less fre-
quent data collection schedule for this outcome.
Qualitative data will be collected via semi-structured, in-
depth telephone interviews and used to clarify and enrich
findings from the quantitative data. The interviews will beFigure 1 Longitudinal study design.conducted either once (for patients in category 1) or, for
some patients in the longitudinal study, at the four time
points described above (see section titled “Qualitative data
collection” for a more detailed description of the inter-
views). The National Jewish Health Institutional Review
Board has approved the study protocol (HS-2790), and the
study is registered on ClinicalTrials.gov (NCT01961362).
Quantitative data collection
Figure 1 gives an overview of the longitudinal arm of the
study. In keeping with the mission and mandates of our
program’s funder, the Patient-Centered Outcomes Re-
search Institute (PCORI), our team selected outcome
measures by democratic process. During round table
discussions, questionnaires were selected from groups of
candidate instruments. Questionnaires will be adminis-
tered and completed online, or, for those who wish, via
paper and pencil and returned via pre-paid envelope.
Online questionnaires will be completed via REDCap
software (http://project-redcap.org/).
The UCSD
The UCSD is a 24-item dyspnea questionnaire that asks
respondents to rate themselves from 0 (“Not at all”) to 5
(“Maximally or unable to do because of breathlessness”)
in two areas: 1) how short of breath they are while per-
forming various activities (21 items); and 2) how much
shortness of breath itself, fear of hurting themselves by
overexerting, and fear of shortness of breath limit them
in their daily lives (3 items). Scores range from 0 to 120,
Table 2 Interview schedule
Category N Interview(s)
1. PF patients who have used O2 for at
least eight months
20 Once
2. ICs of PF patients who have used O2
for at least eight months
20 Once
3. Practitioners who have prescribed O2
for at least one patient with PF
20 Once




2) Just prior to starting
daily-use O2
3) 1 month after starting
daily-use O2
4) 9–12 months after
starting daily-use O2
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UCSD takes 5 minutes to complete.
The Short Form 36-Item Instrument (SF-36)
The SF-36 is a generic health-related QOL (HRQL) ques-
tionnaire with eight domains which comprise two compo-
nent summaries (physical and mental). Each domain and
component is scored from 0–100, with higher scores con-
noting greater HRQL [13]. The SF-36 takes 15 minutes to
complete.
The Fatigue Severity Scale (FSS)
The FSS is a 9-item questionnaire, scored from 9–63,
with higher scores indicating more severe fatigue. The
FSS takes less than five minutes to complete.
The Leicester (pronounced Lester) Cough Questionnaire (LCQ)
The LCQ is a 19-item questionnaire that taps the phys-
ical, psychological and social aspects of cough. Scores
range from 7–63, with higher scores indicating better
cough-related QOL. The LCQ takes five minutes to
complete [14].
Activity monitor
We are capturing physical activity with an accelerometer
—the Actigraph GT3X + Tri-Axis Actigraphy Monitor
(http://www.actigraphcorp.com/). It is a small, light-
weight (19 grams), plastic device (about the size of a
large wristwatch) affixed to an elastic band and comfort-
ably worn around the wrist or waist. The device continu-
ously records data which can be downloaded onto a
computer via a USB cable.
Activity space
We are using a mobile GPS unit—the iGotU GT-600 GPS
data-logger from MobileAction Technologies (http://www.
i-gotu.com/)—to capture activity space. These units are
small and easily worn or carried around by the participant.
They have good reliability and spatial accuracy, even in
urban settings [15]. Activity space is often defined as the
local areas within which people move or travel in the
course of their daily activities and can be used to examine
whether people’s mobility changes during the course of
medical treatment [16]. Recent research suggests that
collecting GPS data on people’s movements is more ac-
curate than travel diaries or semi-structured interviews
which ask participants to recall their activities and
movements throughout the study period [17,18]. Data
from the GPS loggers will be imported into ArcGIS
mapping software and used to create secondary out-
come measures which examine the extent of a partici-
pant’s activity space and how this changes over time
[19-21]. We will ask subjects to keep a trip/travel diaryso we can understand where and why trips outside the
home were taken.
Qualitative data
Table 2 describes the interview schedule. To collect a
wide range of perceptions of O2 we are conducting in-
terviews with 20 PF patients who have used O2 during
the day for at least eight months. Because O2 can poten-
tially affect the entire household of patients who use it
(particularly ICs6), we are interviewing 20 people who
self-identify as ICs of PF patients to get their perspective
of how O2 impacts them and their patient-loved-ones.
To better understand what O2 prescribers expect their
PF patients to gain (and/or endure) when using O2, we
will interview 20 O2 prescribers. To evaluate how PF pa-
tients’ perceptions of O2 change over time, we will inter-
view 40 (of the projected 300) subjects enrolled in the




The goal of the qualitative analysis is to capture the words
participants use to describe their perceptions of O2
whether good or bad. They will be asked how oxygen helps
or deters them from doing what they need or want to do;
how they feel about having to use it; whether there are bar-
riers to its use, and; for patients in the longitudinal arm of
the study, how these change over time. Consistent with
qualitative methodology, analysis is planned as a continu-
ous process beginning with initial interviews and continu-
ing throughout and beyond the data generation period.
After reading and re-reading transcripts to achieve data
immersion, data will be coded following a process of initial
review, with labeling of data by content, process, or im-
pressions of the investigator. The degree of consensus
about particular topics discussed across subjects and over
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also be noted. After this coding is completed, investigators
will organize codes into categories that reflect symbolic
domains of meaning, relational patterns within domains,
and finally overarching themes. Relationships within do-
mains are usually structured according to “organizing
principles”, such as inclusion, symbol, sequence, function,
part-whole, or others. Using this analysis, an analytic sum-
mary of each interview will be written. In the summaries,
the research team will use research participants’ own
words and narratives to preserve the tone and emotion of
their experiences and increase the theoretical depth of the
final description of the effects of O2 on PF patients’ lives.
Narratives, as a specific kind of speech act in the interview
settings, will be indexed in the coding process, and a nar-
rative analysis will ensue. These narratives will be analyzed
for substantive and conceptual meaning along with inter-
view discourse. Comparisons across subjects and over time
within each subject will add detail and depth to the dimen-
sions of the effects of O2.
The software package ATLAS.ti will be used to analyze
the qualitative data. As a theory-building qualitative
package, ATLAS.ti will be used to code the data, to help
the investigators record memos and insights about the
data, and to build and test theories.Quantitative data
We will use paired t tests for the primary and secondary
endpoints. The standard deviational ellipse (both one
and two standard deviations) will be used as measures of
activity space [22]. Because we are collecting longitu-
dinal data, in certain exploratory analyses, we will also
use longitudinal analytic methods—mixed-effects models
will be employed here—to compare the various out-
comes across multiple time points while controlling for
potentially influential variables. We will conduct certain
analyses with the sample stratified on type of pulmonary
fibrosis using clinical data acquired from the subjects’
treating physicians. All statistical analyses will be con-
ducted using SAS (SAS, Inc.; Cary, NC).Sample size
For the primary outcome, change in UCSD score from
baseline to one month after daily supplemental oxygen
use, assuming a conservative correlation of 0.5 between
baseline and one-month UCSD scores, a standard devi-
ation of UCSD change scores of 16 [23], and a two-
tailed alpha value of 0.05, 83 subjects are needed to have
80% power to detect a 5-point difference in UCSD
scores from baseline to one month. We will enroll 300
subjects, conservatively assuming 100 will be prescribed
supplemental oxygen during the first two years of the
study period.Discussion
Our team from the P3F has designed a mixed-methods
study of O2 in PF. The study was, in part, developed by
PF patients for PF patients. To ensure an impactful
study, our team selected meaningful outcomes that span
a diverse spectrum of constructs. For PF patients, whose
daily struggles include managing symptoms of cough, fa-
tigue and dyspnea-imposed limitations in physical activ-
ity (including activities of daily living), outcomes that
assess how patients feel and function seemed most ap-
propriate to our team. Only patients know how they
truly feel (physically and emotionally), and using a range
of patient-reported outcome measures (PROs) is an ideal
way to capture patients’ perceptions.
How best to assess physical functioning among pa-
tients with PF is not known. The six-minute walk test
(6MWT) is frequently used clinically and in research to
assess exercise capacity in PF patients [24]; however,
outside the rigorous confines of a therapeutic trial, the
6MWT is fraught with challenges, including poor repro-
ducibility, non-standardized administration and manage-
ment of O2 during the test [25,26]. Additionally, the
6MWT is an artificial stressor and does not replicate
how a patient would normally accomplish the task of
walking from point A to point B. Most importantly, the
6MWT may tell nothing about how a PF patient func-
tions around the house or whether they are able or will-
ing to leave their home day-to-day. We expect the
accelerometer and GPS data will. Moreover, the 6MWT
is unable to incorporate the influence of O2 on these pa-
rameters. For example, when using O2, PF patients may
be more willing to leave the home, because they have
greater energy and less dyspnea; or, they may not want
to deal with the hassles of getting their O2 tanks ready
or to be seen in public using O2. Many patients who
need O2—not just PF patients—are embarrassed when
using O2 in public places and perceive they are viewed
by others as “sick” or “weak [6,27,28]”. These emotions
and perceptions may change over time (as patients adapt
to their evolving disease state). Our study design will
allow us to capture those changes—and resultant behav-
ioral modifications—if they occur.
We recognize that our study has limitations. In choos-
ing the pre-/post- design (as opposed to, say, a random-
ized trial), we know there is a greater potential for bias.
When designing any study, investigators have to make
concessions. Our team places great value in the “real
world” design and implementation of this study; the
downstream effects of this pragmatic approach are that
results from this research will be extremely far-reaching—
applicable to PF patients nationwide, whereas data from
randomized trials often are not.
We have attempted to design several safety nets to en-
sure data collection occurs just prior to subjects starting
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“need” O2 urgently (e.g., suffer an acute decline in their
PF or are placed on O2 to treat another acute process,
like pulmonary embolism) to wait before starting day-
time O2. Research coordinators will know when subjects
have appointments with their doctors. They will follow-
up with subjects after their appointments to assess
whether daily-use O2 was recommended/prescribed and
implement the seven-ten-day delay for data collection.
Having subjects complete the UCSD every month (24
items, 5 minutes to complete) will keep them engaged in
the study and make it less likely for data to be missing.
We considered limiting enrollment in the longitudinal
study to patients who are not using O2 at all (e.g., no
nocturnal oxygen). However, what often happens is that
patients “ease” into O2 use: initially it is prescribed for
nighttime use only, and then later—if/when PF pro-
gresses—they are prescribed it for daytime use. Excluding
subjects already on nocturnal oxygen could significantly
hinder our ability to enroll the study. Thus, we decided
that patients not using O2 during the day (even if they are
using it at night) would be eligible. In both qualitative and
quantitative analyses, we will examine differences between
subjects who, at enrollment, are not on O2 at all and those
who are using it at night.
Conclusions
We believe we have achieved a balance between the de-
mands the study imposes on subjects and the benefits of
the knowledge the PF field will gain once the study is
completed. And despite its limitations, we also believe
we have designed an informative study whose successful
completion will yield a compilation of data that begins
to fill the information vacuum that currently exists
around the issue of whether O2 benefits patients with
PF. These data will propel the field to a new level of un-
derstanding of whether/how O2 improves how PF pa-
tients feel or function and provide the evidence patients
and prescribers need to make informed decisions about
O2. Because of the mixed-methodology we employ in
this project, we will also be able to tease out why certain
patients do not benefit from O2. We will identify the lo-
gistical and psychological barriers which prevent people
from consistently or effectively using O2, and we can use
this newfound understanding to begin to devise ways we
can all work together—physicians, patients, loved ones,
suppliers, manufacturers, etc.—to improve the overall
O2 experience.
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